KENNETH MCCLAIN to MAP Kinase Signaling System
This is a "connection" page, showing publications KENNETH MCCLAIN has written about MAP Kinase Signaling System.
Connection Strength
0.539
-
Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1882-1887.
Score: 0.189
-
CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018 06 15; 124(12):2607-2620.
Score: 0.125
-
RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med. 2018 01 02; 215(1):319-336.
Score: 0.123
-
International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022 04 28; 139(17):2601-2621.
Score: 0.041
-
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020 05 28; 135(22):1929-1945.
Score: 0.036
-
Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014 Nov 06; 124(19):3007-15.
Score: 0.024